CRME Stock News 8.41 05/13/2014 03:50:24 Cardiome Pharma Corp

New Post Public Reply Private Reply Replies (0) Message Board

May 13, 2014 at 4:50 AM

Cardiome Pharma Corp (CRME) 8.41 $CRME

Cardiome Reports First Quarter 2014 Financial Results
PR Newswire - Mon May 12, 3:15PM CDT
Cardiome to conduct conference call and webcast today, May 12, at 5:00 p.m. Eastern (2:00 p.m. Pacific)

Atrial Fibrillation - Pipeline Review, H1 2014
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrx455/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ARCA biopharma, Inc. - Armetheon, Inc. - Cardiome Pharma Corp - Daiichi Sankyo Company, Limited - Gilead Sciences, Inc. - HUYA Bioscience International, LLC - Isis Pharmaceuticals, Inc. - Laboratoires Pierre Fabre SA - Milestone Pharmaceuticals, Inc. - Nissan Chemical Industries, Ltd. - Nyken BV - Otsuka Holdings Co., Ltd. - Serodus ASA - Xention Limited Drug Profiles: - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - colchicine - bucindolol hydrochloride - vernakalant hydrochloride - budiodarone - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - onabotulinumtoxinA - XEN-D0101 - OPC-108459 - IKACh - XEN-D0104 - HBI-3000 - MSP-2017 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - SER-120 - budiodarone - Drug For Atrial Fibrillation - Adenosine A1 Agonist for Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/zrx455/atrial

Cardiome to hold first quarter 2014 financial results conference call on May 12
CNW Group - Tue May 06, 4:30PM CDT
NASDAQ: CRME TSX: COM

Cardiome Announces Commercialization Agreement with UDG Healthcare plc for BRINAVESS(TM) in Ireland
PR Newswire Europe - Mon May 05, 6:01AM CDT
VANCOUVER, British Columbia, May 5, 2014 /PRNewswire/ --

Cardiome Announces Commercialization Agreement With UDG Healthcare plc For BRINAVESS(TM) In Ireland
CNW Group - Mon May 05, 6:00AM CDT
NASDAQ: CRME TSX: COM

Cardiome Announces Commercialization Agreement With UDG Healthcare plc For BRINAVESS™ In Ireland
PR Newswire - Mon May 05, 6:00AM CDT
NASDAQ: CRME TSX: COM

Flamel Technologies SA (FLML) Soars: Stock Up 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:39AM CDT
Flamel Technologies SA was a big mover last session, as its shares rose nearly 7% on the day.

Cardiome Pharma Shares Down 10.4% Since SmarTrend's Sell Call (CRME)
Comtex SmarTrend(R) - Wed Apr 16, 9:18AM CDT
SmarTrend identified a Downtrend for Cardiome Pharma (NASDAQ:CRME) on March 31st, 2014 at $7.99. In approximately 2 weeks, Cardiome Pharma has returned 10.39% as of today's recent price of $7.16.

PharmAthene (PIP) Crumbles: Stock Falls by 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
PharmAthene saw a big move last session, as the company’s shares fell by over 7% on the day

Flamel Technologies (FLML) Jumps: Stock Adds 9.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:51AM CDT
Flamel Technologies SA was a big mover last session, as its shares rose nearly 10% on the day.

Catalyst Pharmaceutical Partners Inc. (CPRX) Jumps: Stock Up 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:51AM CDT
Catalyst Pharmaceutical Partners Inc. was a big mover last session, as its shares rose nearly 9% on the day.

Cardiome Pharma Has Returned 41.3% Since SmarTrend Recommendation (CRME)
Comtex SmarTrend(R) - Mon Mar 31, 4:47PM CDT
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 21st, 2013 at $5.60. In approximately 4 months, Cardiome Pharma has returned 41.25% as of today's recent price of $7.91.

Cardiome to commercialise BRINAVESS in Greece through Vianex
M2 - Mon Mar 31, 6:10AM CDT
Canadian specialist pharmaceutical company Cardiome Pharma (NASDAQ:CRME)(TSX:COM) revealed on Friday the launch of a commercialisation and distribution of BRINAVESS (vernakalant IV) in Greece.

Cardiome Enters Agreement with VIANEX S.A. to Commercialize BRINAVESS in Greece
PR Newswire Europe - Fri Mar 28, 6:31AM CDT
VANCOUVER, British Columbia, March 28, 2014 /PRNewswire/ --

Cardiome Enters Agreement With Vianex S.A. To Commercialize BRINAVESS In Greece
CNW Group - Fri Mar 28, 6:30AM CDT
NASDAQ: CRME TSX: COM

Cardiome Reports Fourth Quarter and Full Year 2013 Financial Results
CNW Group - Thu Mar 27, 6:00AM CDT
Cardiome to conduct conference call and webcast today, March 27, at 8:00 a.m. Eastern (5:00 a.m. Pacific)

45.7% Return Seen to Date on SmarTrend Cardiome Pharma Call (CRME)
Comtex SmarTrend(R) - Mon Mar 24, 11:00AM CDT
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 21st, 2013 at $5.60. In approximately 4 months, Cardiome Pharma has returned 45.72% as of today's recent price of $8.16.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kroger, Imprint Team Up for AI-Driven Mastercard

Kroger Teams Up with Imprint for New Credit Card Kroger’s at it again, folks. They're rolling out a shiny new Mastercard, and it's not just any plastic—it’s powered by the AI-driven platform Imprint. Now, what does this mean for you and me? Well, if you're a frequent flyer at Kroger aisles, you might want to pay attention because this card’s offering point...

Varda Space's Dual Launch Signals Orbital Ambitions

It's not every day you see two commercial rockets heading to orbit on the same ride, but that's precisely what Varda Space Industries just pulled off. With the W-8 and W-9 vehicles blasting off together, Varda is positioning itself for a leap in orbital operations. They've hitched a ride aboard SpaceX's Transporter-18 mission, and this is more than just a double...

Athlete Threats: Public Info Fuels Security Risks

Public Exposure: The New Athlete Achilles' Heel Imagine sitting on millions while living in a glass house. That's the kind of predicament today's athletes find themselves in, thanks to the treasure trove of public information spilling their personal lives all over the internet. According to the latest Hush Intelligence Athlete Threat Report 2026, this very exposure has...

Hyundai's Record Q3 Sales: SUVs and Hybrids Lead

Hyundai's Drive to Record Q3 Sales When talking about market moves, Hyundai's recent figures speak louder than most quarterly bells. September 2026 marked a whirlwind of growth for Hyundai Motor America, reporting record-breaking sales numbers not just for the month, but for Q3 as a whole. With a 9% jump from September last year in total vehicle sales and a remarkable 3%...

Concrete Pipe: Foundation of Modern Infrastructure

Reinforced Concrete Pipes Hold Their Ground You know, it might not be the flashiest part of our infrastructure toolkit, but concrete pipe plays a mighty big role behind the scenes. Even in this age of shiny new tech and constantly evolving materials, the classic concrete pipe still packs a punch—especially when you demand something that'll last. Enter Stephanie Ward, a...

Nelson-Jameson Boosts Cold Storage in California Move

An Icy Boost for the West Coast Dairy Player Every now and then, a company gets its cold storage game just right. Nelson-Jameson has added fresh muscle to its Turlock facility in California, making waves with serious logistical upgrades. The company's dogged pursuit of better operational efficiency in dairy processing isn't just about bragging rights. It's plain old good...

SaponiQ Reinvents Body Care with Botanical Soap Bars

Breaking Through with Simple Innovation I'll be the first to say it's not every day you hear about a soap company trying to shake things up in body care like it’s a tech startup, but here’s SaponiQ taking a wild swing at it with their lineup of botanical cleansing bars. These things are whipped up in their own U.S.-based facility using some fancy cold-process...

Maternal Health Index: A New Tool With Big Ambitions

A Fresh Take on Maternal Health Today's all about the Heartland Forward's fresh tool, the Maternal Resiliency Index. It's making a splash at the 2026 Heartland Summit with a lot of promise on its shoulders. Backed by economists and health gurus like Emily Oster and Dr. Neel Shah, this index ain't your run-of-the-mill tool. It's here to shake the couch coins out of...

Ace Hardware Ups the Stakes with Rewards Days Event

Ace Hardware: Doubling Down with Rewards Ace Hardware's rolling out the red carpet for its loyal customers. Imagine this: exclusive deals on trusted brands and double points on purchases—an incentive any savvy shopper would jump at. From October 6 to 7, those in the Ace Rewards circle have the chance to nab some hefty savings and perks, a move that's more than just a...

Nukleus Launches Unified Platform for Athletes' Business

Leveling the Business Field for Athletes Athletes spend their lives fighting for every inch on the field, and now Nukleus is giving them the tools to hold ground off it. Why should they be the last ones to know their own business? Ashton Jeanty and Nukleus got tired of that narrative and kicked off a platform today with a real promise: putting an athlete's entire business...